These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 9309098)

  • 1. Adjuvant chemotherapy for testicular cancer.
    Xiao H; Sheinfeld J; Motzer RJ
    Surg Oncol Clin N Am; 1997 Oct; 6(4):863-78. PubMed ID: 9309098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin-based chemotherapy after retroperitoneal lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors.
    Culine S; Theodore C; Farhat F; Bekradda M; Terrier-Lacombe MJ; Droz JP
    J Surg Oncol; 1996 Mar; 61(3):195-8. PubMed ID: 8637206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy for stage II nonseminomatous testicular cancer: what is its role?
    Motzer RJ
    Semin Urol Oncol; 1996 Feb; 14(1):30-3. PubMed ID: 8833386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy for stage II nonseminomatous germ-cell tumors.
    Kondagunta GV; Motzer RJ
    Semin Urol Oncol; 2002 Nov; 20(4):239-43. PubMed ID: 12489056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.
    Böhlen D; Borner M; Sonntag RW; Fey MF; Studer UE
    J Urol; 1999 Apr; 161(4):1148-52. PubMed ID: 10081858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
    Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
    J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy.
    Kondagunta GV; Sheinfeld J; Mazumdar M; Mariani TV; Bajorin D; Bacik J; Bosl GJ; Motzer RJ
    J Clin Oncol; 2004 Feb; 22(3):464-7. PubMed ID: 14752068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Management of stage I testicular nonseminomatous germ cell tumors with an embryonic carcinomatous component. 18 cases].
    Drianno N; Robert M; Legouffe E; Guiter J; Navratil H
    Prog Urol; 1997 Sep; 7(4):622-7. PubMed ID: 9410322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
    Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy for stage II nonseminomatous germ cell tumors.
    Kondagunta GV; Motzer RJ
    Urol Clin North Am; 2007 May; 34(2):179-85; abstract ix. PubMed ID: 17484923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors.
    Motzer RJ; Sheinfeld J; Mazumdar M; Bajorin DF; Bosl GJ; Herr H; Lyn P; Vlamis V
    J Clin Oncol; 1995 Nov; 13(11):2700-4. PubMed ID: 7595727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laparoscopic retroperitoneal lymph node dissection combined with adjuvant chemotherapy for pathological stage II disease in nonseminomatous germ cell tumours: a 15-year experience.
    Cresswell J; Scheitlin W; Gozen A; Lenz E; Teber D; Rassweiler J
    BJU Int; 2008 Sep; 102(7):844-8. PubMed ID: 18537954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
    Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
    J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary chemotherapy for stage 2 testis cancer.
    Abratt RP; McAdam GL; Pontin AR; Barnes RD; Ball HS
    S Afr J Surg; 1997 Nov; 35(4):203-5; discussion 205-6. PubMed ID: 9540399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy for good-risk germ-cell tumors.
    Ryan CJ; Bajorin DF
    Semin Urol Oncol; 2002 Nov; 20(4):244-50. PubMed ID: 12489057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
    Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial.
    Pectasides D; Skarlos D; Dimopoulos AM; Farmakis D; Pectasides M; Fountzilas G; Aravantinos G
    Anticancer Res; 2003; 23(5b):4239-44. PubMed ID: 14666633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
    Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
    J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): a risk adapted protocol of the Hellenic Cooperative Oncology Group.
    Bamias A; Aravantinos G; Kastriotis I; Alivizatos G; Anastasiou I; Christodoulou C; Gyftaki R; Kalofonos HP; Dimopoulos MA
    Urol Oncol; 2011; 29(2):189-93. PubMed ID: 19362863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion.
    Chevreau C; Mazerolles C; Soulié M; Gaspard MH; Mourey L; Bujan L; Plante P; Rischmann P; Bachaud JM; Malavaud B
    Eur Urol; 2004 Aug; 46(2):209-14; discussion 214-5. PubMed ID: 15245815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.